Semaglutide vs Tirzepatide vs Retatrutide (2026)

The most-studied metabolic research peptides of the last decade share a common ancestor — the incretin system — but represent three distinct generations of receptor engineering. Understanding how they differ mechanically is the clearest way to understand why researchers study them separately. This is a science overview for research context only; it is not usage guidance.

The incretin system, briefly

Incretins are hormones the gut releases in response to nutrients. Two matter here: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Each acts on its own receptor. The three compounds below differ by *how many* of these receptor pathways they engage — and that difference is the whole story.

Semaglutide — single agonism (GLP-1)

Semaglutide is a GLP-1 receptor agonist. Structurally it's a modified analog of native GLP-1, engineered for a longer research half-life than the natural hormone, which degrades in minutes. In research settings it's the most extensively characterized of the three, with the longest body of published literature behind it. Mechanistically it engages one receptor pathway: GLP-1.

Tirzepatide — dual agonism (GLP-1 + GIP)

Tirzepatide is engineered to activate two receptors — GLP-1 and GIP — from a single molecule. This dual-agonist design was the first of its kind to reach large-scale study, and much of the research interest centers on how simultaneous GIP engagement changes the signaling profile compared to GLP-1 alone. It's structurally distinct from semaglutide, not a modification of it.

Retatrutide (Ares GLP-3RT) — triple agonism (GLP-1 + GIP + glucagon)

Retatrutide adds a third receptor to the pattern: the glucagon receptor, alongside GLP-1 and GIP. It's the newest of the three and the least characterized, with research still comparatively early. The glucagon-receptor arm is what makes it mechanically different from anything before it. Ares Research supplies this compound as [GLP-3RT](/research/hubs/glp-3rt).

Mechanism at a glance

| Compound | Receptors engaged | Generation | Research maturity | |---|---|---|---| | Semaglutide | GLP-1 | Single agonist | Most established | | Tirzepatide | GLP-1 + GIP | Dual agonist | Well-studied | | Retatrutide (GLP-3RT) | GLP-1 + GIP + glucagon | Triple agonist | Earliest-stage |

Why the distinction matters for research

Each added receptor pathway changes the signaling picture, which is precisely why these are studied as separate compounds rather than interchangeable ones. The progression from single to triple agonism is one of the clearer examples of iterative peptide engineering in the recent literature — and why "which receptors does it hit" is the first question in any comparison.

*Educational / research context only. Ares Research supplies compounds for laboratory and research use. This content is not medical advice and describes no human use, dosing, or protocol.*

Related reading

• GLP-3RT (Ares)
• GLP-1S
• GLP-2T
• Testing & COA transparency